trending Market Intelligence /marketintelligence/en/news-insights/trending/zWTkQdBTOaQv1--cbd1eog2 content esgSubNav
In This List

Li Kang Biomedical swings to profit in Q2


Street Talk | Episode 105: Banks could see opportunity in fintech's cleansing fire


The Climate Vulnerability Assessment by APRA: Helping Financial Institutions Address Challenges


Lithium Import


Activity Volumes Across the Equity Capital Markets Dropped Significantly in 2022

Li Kang Biomedical swings to profit in Q2

Li Kang Biomedical Co. Ltd. said its normalized net income for the second quarter amounted to 57 Taiwan cents per share, compared with a loss of 27 cents per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$12.6 million, compared with a loss of NT$2.2 million in the prior-year period.

The normalized profit margin rose to 8.8% from negative 4.5% in the year-earlier period.

Total revenue increased on an annual basis to NT$142.9 million from NT$48.8 million, and total operating expenses climbed on an annual basis to NT$123.0 million from NT$52.2 million.

Reported net income totaled NT$20.1 million, or 91 cents per share, compared to a loss of NT$2.8 million, or a loss of 34 cents per share, in the prior-year period.

As of Aug. 11, US$1 was equivalent to NT$32.22.